Exscientia
Exscientia enters AI drug discovery collaboration with Merck KGaA
September 20, 2023Business Services AI, Exscientia, Immunology, Merck KGaA, Neurology, Oncology, collaboration, drug discovery
Exscientia has announced a new collaboration with Merck KGaA, Darmstadt, Germany, with a focus on the discovery of novel small …
Exscientia to collaborate with EQRx on drug development
June 25, 2021Medical Communications AI, Exscientia, clinical drug development
Exscientia and EQRx have announced a strategic research and development collaboration agreement aiming to substantially accelerate the delivery of novel …
Exscientia launch trial of third AI-designed molecule
May 13, 2021AI, Altzeimer's, Exscientia
Exscientia has launched Phase I trials in the US of DSP-0038 for the treatment of Alzheimer’s disease psychosis, the third …
Exscientia enter first-ever AI cancer drug into Phase I trials
April 9, 2021Medical Communications AI, Evotec, Exscientia, cancer treatment, oncology, pharma, pharma news
Exscientia and Evotec have announced that they are entering an AI-designed immuno-oncology drug into Phase I trials for the first …
Allergan R&D Chief named as Chairman of Exscientia’s Board of Directors
October 8, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Exscientia, appointment
Artificial intelligence-driven drug discovery firm Exscientia has named industry veteran Dr David Nicholson, current Executive Vice President and Chief R&D …
AI firm Exscientia appoints COO and Head of Drug Discovery
January 31, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Exscientia, appointment
AI drug discovery firm Exscientia has announced the appointment of Dr David Hallett as its Chief Operating Officer and Head …
Bayer and Exscientia to work together on AI in cardiovascular and oncology drug discovery
January 10, 2020Medical Communications Bayer, Exscientia, oncology
Bayer AG has partnered with Exscientia to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology. …
Celgene inks drug discovery deal worth at least £25m with AI firm Exscientia
March 21, 2019Research and Development Celgene, Exscientia, drug discovery, pharma
Celgene has entered into a new three-year partnership with British artificial intelligence and drug discovery firm Exscientia to the value …
The future is now: The transformative power of AI
February 5, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Exscientia, GSK, GlaxoSmithKline, artificial intelligence, drug development, pharma
With the technologies reaching exciting levels of maturity and adoption, Matt Fellows investigates how AI and machine learning can be …
Exscientia appoints Oxford Innovation Sciences founder and ex-Lansdowne CEO as Deputy Chairman
December 11, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alex Snow, Exscientia, appointment
Exscientia, an Oxford-based drug design firm which has made headlines this year for its collaboration with GlaxoSmithKline to leverage its …
GSK signs $43 million AI-based drug discovery deal with Exscientia
July 3, 2017Research and Development, Sales and Marketing AstraZeneca, Exscientia, GSK
With AI partnerships becoming increasingly common in the life sciences industry, it has emerged that GSK is to partner up …
